28 filings · most recent first
ALNY 8-K Filings
Alnylam Pharmaceuticals Reports Strong Q2 2026 Financial Results And Revises
Alnylam Pharmaceuticals Expands Board And Announces Annual Meeting Results
Alnylam Pharmaceuticals Reports Strong Q1 2026 Financial Results And Strategic
Alnylam Pharmaceuticals Inc Grants Special Equity Award To Ceo Yvonne
Alnylam Pharmaceuticals Reports Strong Q4 2025 Financial Results And Highlights
Alnylam Announces New Fiveyear Strategy And Preliminary 2025 Financial Results
Alnylam Appoints New Director And Announces Board Resignations
Alnylam Pharmaceuticals Reports Strong Q3 2025 Financial Results And Raises
Alnylam Pharmaceuticals Announces Partial Repurchase Of Convertible Senior Notes
Alnylam Pharmaceuticals Enters Into A 500M Credit Agreement
Alnylam Pharmaceuticals Completes Convertible Notes Offering
Alnylam Announces Convertible Senior Notes Offering
Alnylam Pharmaceuticals Announces Departure Of Chief Legal Officer
Alnylam Pharmaceuticals Announces Transition Of Executive Vice President And Clo
Alnylam Pharmaceuticals Announces Preliminary 2023 Financial Results And Updates
Alnylam Pharmaceuticals Reports Strong Q2 2025 Financial Results And Raises
Alnylam Promotes Pushkal Garg To Chief Research And Development Officer
Alnylam Pharmaceuticals Approves Bylaw Amendment And Reelects Directors
Alnylam Pharmaceuticals Announces Q1 2025 Financial Results And Key Approvals
Alnylam Pharmaceuticals Announces Fda Approval Of Amvuttra For Attrcm
Dr Phillip A Sharp To Retire From Alnylam Board Of Directors
Alnylam Pharmaceuticals Reports Q4 2024 Financial Results
Alnylam Pharmaceuticals Announces Preliminary 2024 Financial Results And 2025
Alnylam Pharmaceuticals Announces Quarterly Financial Results
Alnylam Pharmaceuticals Reports Strong Q2 2024 Financial Results And Key Updates
Alnylam Pharmaceuticals Reelects Board Members And Approves Executive
Alnylam Pharmaceuticals Reports Strong Q1 2024 Financial Results
Alnylam Pharmaceuticals Reports Strong 2023 Financial Performance And Sets 2024